CTPS2 Antibody

How do CTPS2 antibodies differ in their binding specificity and applications?

CTPS2 antibodies vary in their binding specificity based on the epitope region they target. Antibodies are available that target different regions including:

• N-terminal regions (e.g., AA 77-105)

• C-terminal regions (e.g., AA 450-479)

• Mid-region epitopes (e.g., AA 170-219)

This epitope diversity allows researchers to select antibodies optimal for different applications. For instance, some antibodies work particularly well for Western blot analysis but may be less effective for immunohistochemistry. Application suitability is typically indicated by validation data provided by manufacturers . Polyclonal antibodies often provide broader epitope recognition, while monoclonal antibodies offer higher specificity for a single epitope .

What species reactivity should be considered when selecting a CTPS2 antibody?

CTPS2 antibodies demonstrate different cross-reactivity profiles across species. When selecting an antibody, researchers should confirm reactivity with their target species. Many commercially available CTPS2 antibodies show reactivity with human, mouse, and rat samples . Some antibodies offer broader cross-reactivity with species such as dog, horse, cow, pig, rabbit, and zebrafish . The sequence homology between human CTPS2 and orthologs (e.g., 86% identity with mouse and rat ) influences cross-reactivity. Researchers should review validation data specific to their species of interest before selection.

How should CTPS2 antibodies be validated for specific research applications?

Rigorous validation of CTPS2 antibodies should include:

• Specificity testing:

  • Western blot analysis using positive control samples known to express CTPS2 (e.g., HEK293 cells, HeLa cells)

  • Knockout validation using CTPS2-KO cell lines generated through CRISPR-Cas9

  • Peptide competition assays to confirm epitope specificity

• Application-specific validation:

  • For WB: Testing across multiple cell lines with varying CTPS2 expression levels

  • For IHC/IF: Assessment of tissue-specific staining patterns with appropriate controls

  • For IP: Confirmation of pull-down efficiency with subsequent Western blot detection

• Cross-reactivity assessment:

  • Testing potential cross-reactivity with CTPS1 due to structural similarities

  • Species-specific validation if working with non-human samples

Validated antibodies should produce consistent results showing the expected molecular weight (~66 kDa) for CTPS2 .

What are the optimal protocols for using CTPS2 antibodies in Western blot analysis?

Optimal Western blot protocols for CTPS2 antibodies typically include:

Sample preparation:

• Lyse cells in RIPA buffer with protease inhibitors

• For analysis of phosphorylated CTPS2, include phosphatase inhibitors in lysis buffer

Gel electrophoresis:

• Use 10% SDS-PAGE gels for optimal separation around the 66 kDa region

• Load 20-50 μg of total protein per lane depending on expression level

Transfer and detection:

• Transfer to PVDF or nitrocellulose membranes (0.45 μm pore size)

• Block with 5% non-fat milk or BSA in TBST for 1 hour at room temperature

• Primary antibody dilutions:

  • Polyclonal antibodies: 1:500-1:2000

  • Monoclonal antibodies: 1:2000-1:10000

• Incubate with primary antibody overnight at 4°C

• Secondary antibody incubation: 1-2 hours at room temperature

• Visualization by chemiluminescence or infrared detection systems

Controls:

• Include positive control samples (e.g., HEK293, HeLa cells)

• Consider testing CTPS2-KO cells as negative controls

What cell lines and tissues are recommended as positive controls for CTPS2 antibody experiments?

Recommended positive controls for CTPS2 antibody experiments include:

Cell lines with confirmed CTPS2 expression:

• HEK293 cells (high expression of both CTPS1 and CTPS2)

• HeLa cells

• HepG2 cells

• K-562 cells

• LNCaP cells

• U2OS cells

Cell lines with differential CTPS1/CTPS2 expression:

• Jurkat cells (express CTPS1 but not CTPS2)

• CCRF-CEM cells (express both CTPS1 and CTPS2)

Tissue samples with confirmed CTPS2 expression:

• Human colon tissue

• Human prostate cancer tissue

• Human adrenal gland tissue

• Mouse testis tissue

The differential expression across cell lines can be useful for antibody validation and specificity testing .

How can researchers optimize immunoprecipitation (IP) protocols with CTPS2 antibodies?

Optimizing immunoprecipitation of CTPS2 requires careful consideration of several factors:

Lysis conditions:

• Use gentle lysis buffers (e.g., NP-40 or RIPA buffer with 5 μg/ml leupeptin) to preserve native protein structure

• Include protease inhibitors to prevent degradation during preparation

IP protocol optimization:

• Antibody amount: Use 0.5-4.0 μg antibody for 1.0-3.0 mg of total protein lysate

• Pre-clearing: Remove non-specific binding proteins with protein A/G beads before adding antibody

• Incubation time: Overnight incubation at 4°C typically yields optimal results

• Washing stringency: Balance between removing non-specific binding and retaining specific interactions

Controls for IP experiments:

• IgG control: Use matched isotype IgG to identify non-specific binding

• Input control: Include 5-10% of pre-IP lysate for comparison

• Known interaction partners: Consider co-IP of established CTPS2-interacting proteins

Detection methods:

• Western blot: Use 1 μg/ml of CTPS2 antibody for detecting immunoprecipitated CTPS2

• For phosphorylation studies: Incorporate [γ-32P]H3PO4 labeling approaches

Successfully immunoprecipitated CTPS2 can be verified by Western blot, showing a band at approximately 66 kDa .

What are the potential causes of inconsistent CTPS2 antibody staining in immunohistochemistry applications?

Inconsistent CTPS2 staining in IHC applications may result from several factors:

Fixation and tissue processing issues:

• Overfixation with formalin can mask epitopes

• Inadequate antigen retrieval may prevent antibody access to epitopes

• Different tissue processing methods can affect epitope preservation

Antibody-specific considerations:

• Suboptimal antigen retrieval methods for the specific epitope

• Inappropriate antibody dilutions (recommended range: 1:500-1:2000 for polyclonal , 1:250-1:1000 for monoclonal )

• Batch-to-batch variations in antibody performance

Biological variations:

• Variable CTPS2 expression levels across different cell types within a tissue

• Post-translational modifications affecting epitope recognition

• Expression differences between normal and pathological samples

Technical remedies:

• Optimize antigen retrieval: Both TE buffer pH 9.0 and citrate buffer pH 6.0 have been successful for CTPS2 IHC

• Titrate antibody concentration for each application

• Include positive control tissues with confirmed CTPS2 expression

• Consider testing multiple antibodies targeting different epitopes

• Verify specificity with competing peptides

How can CTPS2 and CTPS1 activities be distinguished in functional studies?

Distinguishing between CTPS2 and CTPS1 activities in functional studies requires specialized approaches:

Genetic approaches:

• CRISPR-Cas9 knockout of either CTPS1 or CTPS2 to isolate the contribution of each isoform

• siRNA knockdown for transient suppression of specific isoforms

• Complementation experiments with recombinant CTPS1 or CTPS2 in knockout backgrounds

Biochemical approaches:

• Exploit differential sensitivity to inhibitors: CTPS2 appears more sensitive to 3-deaza-uridine (3-DU) inhibition than CTPS1

• Immunoprecipitation of individual isoforms followed by activity assays

• Expression of tagged versions (e.g., FLAG-tagged) of each isoform for selective isolation

Functional readouts:

• Measure proliferation rates in cells expressing only CTPS1 or CTPS2

• Analyze CTP levels in cells with selective knockout of either isoform

• Use cytidine supplementation to rescue proliferation defects as a measure of CTPS dependency

Data interpretation:

How do CTPS2 expression patterns correlate with cell proliferation status and cancer pathology?

CTPS2 expression shows complex relationships with proliferation and cancer pathology:

Cell proliferation correlations:

• CTPS2 contributes modestly to cell proliferation when CTPS1 is expressed

• CTPS2 becomes essential for proliferation in the absence of CTPS1

• CTPS activity is generally higher in proliferating tissues compared to normal tissues

Cancer cell line expression patterns:

• Variable CTPS2 expression across cancer cell lines:

  • Low or undetectable in some T-lymphoid cancer lines (MOLT-4, HUT-78, Jurkat)

  • Detectable in others (CCRF-CEM, HEK293)

  • Expressed in various solid tumor cell lines (HeLa, HepG2, LNCaP)

Clinical relevance:

• Analysis of over 1,000 cancer cell lines indicates that cell growth is highly dependent on CTPS1 but less or not dependent on CTPS2

• Cancer cells with increased proliferation generally show increased CTPS activity

• CTPS2 is considered a potential target for selective chemotherapy

Research methodologies for studying these correlations:

• Immunohistochemical analysis of CTPS2 expression in tumor vs. normal tissues

• Correlation of CTPS2 expression with proliferation markers (Ki-67, PCNA)

• Analysis of CTPS2 expression and activity in different stages of cancer progression

What are the methodological considerations for studying CTPS2 phosphorylation and other post-translational modifications?

Studying CTPS2 post-translational modifications requires specialized approaches:

Phosphorylation analysis methods:

• Metabolic labeling with [γ-32P]H3PO4 followed by immunoprecipitation

• Phospho-specific antibodies targeting known CTPS2 phosphorylation sites

• Mass spectrometry analysis of purified CTPS2 to identify modification sites

• In vitro kinase assays to identify kinases responsible for CTPS2 phosphorylation

Sample preparation considerations:

• Include phosphatase inhibitors in lysis buffers to preserve phosphorylation status

• Consider cell stimulation conditions that may affect phosphorylation status

• Use appropriate positive controls known to contain phosphorylated CTPS2

Other post-translational modifications:

• Ubiquitination: Use immunoprecipitation coupled with ubiquitin-specific antibodies

• SUMOylation: Apply SUMO-specific antibodies or tagged SUMO constructs

• Acetylation: Employ acetylation-specific antibodies or mass spectrometry approaches

Functional correlation:

• Correlation between phosphorylation status and enzymatic activity

• Site-directed mutagenesis of modification sites to assess functional significance

• Dynamic changes in modifications during cell cycle progression or in response to stress

Technical challenges:

• Low abundance of modified forms requiring enrichment strategies

• Potential loss of modifications during sample processing

• Need for high-sensitivity detection methods

How can researchers accurately measure CTPS2 enzymatic activity and distinguish it from CTPS1 activity?

Measuring specific CTPS2 enzymatic activity presents several methodological challenges:

Selective isolation approaches:

• Immunoprecipitation of CTPS2 using specific antibodies before activity assays

• Expression of tagged CTPS2 (e.g., FLAG-tagged) for selective purification

• Recombinant expression and purification of CTPS2 for in vitro activity assays

Activity assay methodologies:

• Standard CTPS activity assay measuring the conversion of UTP to CTP:

  • Reaction mixture: 50 mM Tricine pH 8.1, 20 mM MgCl2, ATP, UTP, glutamine

  • Measurement of CTP formation by spectrophotometric or HPLC methods

• Radiochemical assays using labeled substrates:

  • [14C]-UTP or [3H]-UTP to track conversion to CTP

  • Separation of substrates and products by TLC or column chromatography

Distinguishing from CTPS1 activity:

• Genetic approaches: Use cells with CTPS1 knockout to measure pure CTPS2 activity

• Inhibitor-based approaches: Exploit differential sensitivity to 3-deaza-uridine

• Kinetic analysis: Compare substrate affinities and reaction velocities

  • CTPS2 appears to have lower affinity for UTP compared to CTPS1

Controls and validation:

• Use cells with confirmed CTPS2 expression but minimal CTPS1 (if available)

• Include negative controls (CTPS2-KO cells) to establish background levels

• Validate activity measurements with complementary approaches (e.g., CTP level measurements)

What are the methodological approaches for investigating CTPS2 filament formation and its biological significance?

CTPS enzymes can form filamentous structures, and investigating this property for CTPS2 requires specialized approaches:

Visualization methods:

• Immunofluorescence microscopy using validated CTPS2-specific antibodies

• Live-cell imaging using fluorescently-tagged CTPS2 constructs

• Super-resolution microscopy (STORM, PALM) for detailed structural analysis

• Electron microscopy for ultrastructural characterization

Induction and regulation of filament formation:

• Test various metabolic stresses known to induce CTPS filament formation

• Evaluate nucleotide depletion conditions (glutamine starvation, nucleotide synthesis inhibitors)

• Analyze effects of cell cycle phases on filament dynamics

Functional significance assessment:

• Correlation between filament formation and CTPS2 enzymatic activity

• Mutagenesis of domains involved in filament formation

• Co-localization with other metabolic enzymes forming similar structures

• Effects of filament disruption on cellular CTP levels and proliferation

Comparative analysis with CTPS1:

• Differential regulation of filament formation between CTPS1 and CTPS2

• Co-assembly potential (mixed filaments) of CTPS1 and CTPS2

• Cell-type specific patterns of filament formation

How do researchers address contradictory findings regarding CTPS2 expression and function across different cell types?

Addressing contradictory findings in CTPS2 research requires systematic approaches:

Standardization of detection methods:

• Use multiple validated antibodies targeting different epitopes

• Apply complementary approaches (Western blot, qRT-PCR, proteomics)

• Include appropriate positive and negative controls

• Standardize protein extraction and handling procedures

Biological explanations for contradictions:

• Cell-type specific expression patterns (e.g., variability in T-cell lines)

• Potential alternative splicing affecting antibody recognition

• Post-translational modifications masking epitopes

• Compensation mechanisms in different genetic backgrounds

Experimental design considerations:

• Clear documentation of cell culture conditions affecting expression

• Passage number and cell density effects on expression

• Consider differences between in vitro models and in vivo tissues

• Account for dynamic regulation under different physiological states

Reconciliation strategies:

• Direct side-by-side comparison of different antibodies and methods

• Genetic validation using CRISPR-Cas9 to generate reference standards

• Multi-laboratory validation of key findings

• Meta-analysis of published data with attention to methodological differences

What experimental approaches can elucidate the interplay between CTPS1 and CTPS2 in different cellular contexts?

Understanding CTPS1-CTPS2 interplay requires multifaceted experimental strategies:

Genetic manipulation approaches:

• Single and double knockout models using CRISPR-Cas9

• Inducible expression systems to control the ratio of CTPS1:CTPS2

• Complementation studies with wild-type or mutant constructs

• Domain-swapping between CTPS1 and CTPS2 to identify functional differences

Biochemical interaction studies:

• Co-immunoprecipitation to assess physical interaction between CTPS1 and CTPS2

• Proximity labeling approaches (BioID, APEX) to map interaction networks

• Bimolecular fluorescence complementation to visualize interactions in living cells

• In vitro studies with purified proteins to assess direct interactions

Functional assays:

• Proliferation analysis in cells with defined CTPS1:CTPS2 ratios

• Cytidine rescue experiments to assess CTP synthesis dependency

• Enzymatic activity measurements in various genetic backgrounds

• Metabolomic analysis of nucleotide pools in different knockout/overexpression models

Cell-type specific analyses:

• Comparison between cell types with different natural CTPS1:CTPS2 ratios

• Analysis of differential regulation in normal versus cancer cells

• Tissue-specific knockout models to assess context-dependent roles

• Primary cell isolation from different tissues for comparative studies